Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | FOS | P01100 | 1/20 | 0.31 |
| ▸ | JUN | P05412 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21341722 | 0.82 | KDM4E (0.30) | — | |
| SCHEMBL21398078 | 0.80 | NOS3 (0.37) | NOS3NOS1NOS2FOSJUN | |
| SCHEMBL21398074 | 0.80 | NOS3 (0.33) | NOS3NOS1NOS2FOSJUN | |
| SCHEMBL21341344 | 0.79 | LMNA (0.42) | — | |
| SCHEMBL15429616 | 0.78 | DHFR (0.45) | NOS3NOS1NOS2 | |
| SCHEMBL10235091 | 0.78 | DHFR (0.41) | NOS3NOS1NOS2 | |
| SCHEMBL10233516 | 0.76 | DHFR (0.33) | NOS3NOS1NOS2FOSJUN | |
| SCHEMBL12563208 | 0.76 | POLB (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL10235454 | 0.76 | MCHR1 (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL10235456 | 0.76 | FOS (0.36) | NOS3NOS1NOS2FOSJUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230295130-A1 | COMPOUND USEFUL AS CDK7 KINASE INHIBITOR AND USE THEREOF | TYK MEDICINES, INC. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295130-A1 | COMPOUND USEFUL AS CDK7 KINASE INHIBITOR AND USE THEREOF | TYK MEDICINES, INC. (CN) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | NOS3 3270/4885NOS1 2959/4885NOS2 2730/4885 |
| US-20230295130-A1 | COMPOUND USEFUL AS CDK7 KINASE INHIBITOR AND USE THEREOF | CDK7, CDK6, CDK9 | NOS3 4157/4885NOS1 3804/4885NOS2 3903/4885 |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | EGFR, ERBB2, CBL | NOS3 4673/4885NOS1 4700/4885NOS2 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.